AGT Gene: Salt-Sensitive Hypertension, Angiotensinogen, and the M235T Variant

How the RAAS System Controls Blood Pressure

The renin-angiotensin-aldosterone system is the primary long-term regulator of blood pressure and sodium balance. Understanding the cascade clarifies exactly where AGT M235T intervenes:

1. Renin is released by the kidney when blood pressure falls or sodium delivery to the distal tubule decreases. Renin cleaves angiotensinogen (produced by the liver).
2. Angiotensinogen → cleaved by renin → Angiotensin I (inactive 10-peptide)
3. ACE (angiotensin-converting enzyme) cleaves Angiotensin I → Angiotensin II (active 8-peptide)
4. Angiotensin II acts on AT1 receptors to: raise blood pressure (vasoconstriction), stimulate aldosterone release from adrenal glands, promote kidney sodium and water retention, and increase thirst.

Angiotensinogen is the substrate for the entire cascade. The M235T variant increases angiotensinogen production by the liver — estimated 10-20% higher plasma levels in TT versus MM homozygotes in multiple studies. This upstream increase provides more substrate for angiotensin II generation, effectively raising the RAAS activity setpoint.

Critically, this doesn't cause uniformly high blood pressure — it makes blood pressure more responsive to sodium intake. When sodium is high, TT individuals retain more sodium and water (via aldosterone), resulting in higher blood pressure. When sodium is low, the effect is less pronounced because the RAAS is activated to conserve sodium regardless of genotype. This is the definition of salt sensitivity: the same sodium intake produces a larger blood pressure response.

The Research Foundation: What M235T Actually Does

The M235T variant was identified as a hypertension risk factor in 1992 by Jeunemaitre et al. in the seminal study published in Cell. They found that the T235 allele was significantly overrepresented in hypertensive individuals and co-segregated with elevated plasma angiotensinogen in affected families.

Subsequent mechanistic work identified why: the T235 substitution (threonine for methionine) in the signal peptide of angiotensinogen alters the protein's secretion efficiency from liver cells. TT individuals secrete angiotensinogen approximately 10-20% more efficiently than MM individuals. In a saturated RAAS pathway (when renin is limiting), this doesn't change much. But under physiological conditions where renin is rate-limiting, higher angiotensinogen substrate increases angiotensin II output.

The clinical consequence varies by population. In East Asians, the T allele frequency is substantially higher (60-80%) and the effect size for hypertension risk appears larger — consistent with the higher hypertension prevalence and stronger salt-sensitivity observed in these populations. A 2001 meta-analysis by Staessen et al. in Journal of Hypertension confirmed the M235T-hypertension association across European cohorts with OR approximately 1.2-1.5 per T allele.

Salt Sensitivity: What It Means in Practice

Salt sensitivity is defined clinically as a greater than 10 mmHg rise in mean arterial pressure when sodium intake increases from low (500 mg/day) to high (6,000 mg/day) levels. Approximately 30-50% of hypertensive individuals and 15-25% of normotensive individuals are salt-sensitive.

The public health relevance: the average American consumes approximately 3,400 mg of sodium daily — nearly 7x the amount sufficient for physiological needs. For TT homozygotes at the M235T variant, this chronic high-sodium exposure chronically elevates blood pressure via the RAAS mechanism described above.

The good news: salt sensitivity is fully reversible with sodium restriction. Unlike genetic elevations of LDL (which require persistent treatment), sodium-sensitive hypertension in AGT T235 carriers responds rapidly and robustly to dietary sodium reduction. A 2001 meta-analysis of controlled DASH-sodium trials found that reducing sodium intake from high to low levels produced the largest blood pressure reductions in individuals with genetic evidence of RAAS hyperactivity — the subgroup that includes M235T TT carriers.

The DASH Diet and Potassium: The Evidence

The DASH diet (Dietary Approaches to Stop Hypertension) was designed empirically before the genetic mechanisms were understood, but its components map precisely to the AGT M235T pathway:

• Sodium restriction: Reduces the substrate available for RAAS-driven sodium retention. The DASH-Sodium trial found that combining the DASH diet with sodium restriction (1,500 mg/day) produced blood pressure reductions of 8-14 mmHg systolic — equivalent to a single antihypertensive medication.
• High potassium: Potassium directly counteracts sodium's blood pressure effects by promoting sodium excretion via the kidney (the natriuretic effect of potassium). DASH diet targets 4,700 mg/day potassium versus the US average of 2,400 mg/day. For M235T TT carriers, potassium supplementation or high-potassium diet is particularly effective.
• Low sodium:potassium ratio: The ratio of sodium to potassium (Na:K ratio) in the urine is a stronger predictor of cardiovascular events than either electrolyte alone. TT carriers benefit from optimizing both — not just restricting sodium but also increasing potassium to shift the ratio.
• Magnesium: Magnesium reduces vascular smooth muscle contractility via calcium channel antagonism. The DASH diet is also high in magnesium (from vegetables, legumes, nuts). Magnesium deficiency worsens blood pressure and is nearly universal in Western diets.

AGT and Interactions with ACE and AT1R Variants

The RAAS pathway involves multiple enzymes and receptors beyond AGT — each encoded by genes with their own common variants. The most clinically relevant interactions:

References